Now open: Broad Agency Announcements

Now open: Broad Agency Announcements for Advanced Research and Development of Medical Countermeasures for Pandemic Influenza and Chemical, Biological, Radiological and Nuclear Threats

BARDA is soliciting proposals for the advanced research and development of medical countermeasures (MCM) such as vaccines, therapeutics, diagnostics and devices. Specifics of the solicitation can be found under three Broad Agency Announcements (BAA), renewed today, which aim to develop MCMs for and support capabilities to address multiple public health threats. The BAAs are:

- BARDA-CBRN-BAA-12-100-SOL-00011 aims to develop MCMs for chemical, biological, radiological, and nuclear (CBRN) agents.

- BARDA-BAA-12-100-SOL-00018 will support development of MCMs for pandemic influenza.

-BARDA-BAA-12-100-SOL-00013 will support innovation through development of platform technologies that enhance capabilities for development and manufacturing of MCMs.

BARDA is working to build a pipeline of candidate medical countermeasures to support the preparedness mission of the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE). Funding through these BAAs will be evaluated with respect to their relevance to medical countermeasure priorities as laid out in the 2007 PHEMCE Implementation Plan for CBRN Threats, the National Strategy for Pandemic Influenza, the 2010 HHS Public Health Emergency Medical Countermeasures Enterprise Review, and the BARDA Strategic Plan 2011-2016.

BARDA anticipates that advanced research and development contracts awarded under these BAAs will advance the maturity and scientific understanding of candidate medical countermeasures, and result in a broader portfolio of products for potential consideration under future procurement activities.

###